Exploring the Impact of Monocytes in Myeloproliferative Neoplasia (EMYNEM)

Impact of monocytes on Myeloproliferative Neoplasm hematopoietic stem cell growth and differentiation in vitro

Recruiting

Interested in participating?

Key information

Conditions

Myeloproliferative Neoplasm Bone Marrow Diseases Hematologic Diseases Hemic and Lymphatic Diseases Myeloproliferative Disorders

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Chu Brest

Brest, 29609, France

Location status: Recruiting

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of MPN in the participating center
Over 18 yo

Exclusion criteria

Not able to consent

Treatment and study plan

Primary outcomes

Proliferation and differentiation of hematopoitic stem/progenitor cells

Time frame: 2 years

Study contacts

Contact information is provided by the study sponsor or research team.

Eric LIPPERT

CONTACT

[email protected]

0298347033 ext. +33

Wayne Corentin LAMBERT

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

University Hospital, Brest

Other

Registry information

Official study title

Exploring the Impact of Monocytes in Myeloproliferative Neoplasia

Acronym: EMYNEM

Important dates

Study start: 2024
Primary completion: 2028
Study completion: 2028
First posted: Jun 17, 2024
Registry last updated: Jun 17, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting